{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T07:55:59Z","timestamp":1781510159728,"version":"3.54.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005851","name":"Shahid Beheshti University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005851","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.msard.2025.106887","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:20:57Z","timestamp":1764202857000},"page":"106887","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Hypogammaglobulinemia and infection risks in multiple sclerosis patients receiving anti-CD20 monoclonal antibodies: Incidence, clinical implications, and longitudinal insights from a three-year Iranian cohort"],"prefix":"10.1016","volume":"106","author":[{"given":"Elham Asl","family":"Fallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Emami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahid Beladi","family":"Moghaddam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehran","family":"Ghaffari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Meshkini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7168-9069","authenticated-orcid":false,"given":"Sepideh","family":"Paybast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.msard.2025.106887_bib0001","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with Rituximab and hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMa Netw. Open."},{"issue":"10","key":"10.1016\/j.msard.2025.106887_bib0002","doi-asserted-by":"crossref","first-page":"5783","DOI":"10.1007\/s10072-022-06287-2","article-title":"Hypogammaglobulinemia is associated with reduced antibody response after anti-SARS-CoV-2 vaccination in MS patients treated with antiCD20 therapies","volume":"43","author":"Bellinvia","year":"2022","journal-title":"Neurol. Sci."},{"issue":"5","key":"10.1016\/j.msard.2025.106887_bib0003","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.jaci.2015.04.049","article-title":"Practice parameter for the diagnosis and management of primary immunodeficiency","volume":"136","author":"Bonilla","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.msard.2025.106887_bib0004","article-title":"Comparative safety profiles of ocrelizumab and rituximab in multiple sclerosis treatment using real-world evidence","author":"Cerono","year":"2025","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2025.106887_bib0005","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000210142","article-title":"Long-term treatment with Ocrelizumab in patients with early-stage relapsing MS","volume":"104","author":"Cerqueira","year":"2025","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2025.106887_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102787","article-title":"Comparison of the efficacy and safety of Anti-CD20 B cells depleting drugs in multiple sclerosis","volume":"49","author":"Cotchett","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2025.106887_bib0008","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/ana.27281","article-title":"Effect of cumulative exposure to ocrelizumab on memory B-cell repopulation dynamics in multiple sclerosis","volume":"98","author":"Disanto","year":"2025","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106887_bib0009","first-page":"15","article-title":"Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 treatments: a systematic review and meta-analysis of 19,139 multiple sclerosis patients","author":"Elgenidy","year":"2024","journal-title":"Front. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2025.106887_bib0010","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.neurol.2023.12.013","article-title":"Anti-CD20 monoclonal antibodies in multiple sclerosis: rethinking the current treatment strategy","volume":"180","author":"Freeman","year":"2024","journal-title":"Rev. Neurol. (Paris)"},{"issue":"8","key":"10.1016\/j.msard.2025.106887_bib0011","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1007\/s10072-025-08098-7","article-title":"Clinical and radiological activity after extended interval and standard interval dosing of ocrelizumab in multiple sclerosis: a systematic review and meta-analysis","volume":"46","author":"Ghajarzadeh","year":"2025","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106887_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101468","article-title":"Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity","volume":"37","author":"Juto","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2025.106887_bib0013","doi-asserted-by":"crossref","first-page":"375","DOI":"10.5603\/pjnns.103955","article-title":"Epidemiology of multiple sclerosis: global trends, regional differences, and clinical implications","volume":"59","author":"Kapica-Topczewska","year":"2025","journal-title":"Neurol. Neurochir. Pol."},{"issue":"2","key":"10.1016\/j.msard.2025.106887_bib0014","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s00415-023-11943-4","article-title":"Ocrelizumab exposure in relapsing\u2013remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension","volume":"271","author":"Kappos","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106887_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00721","article-title":"The maintenance of memory plasma cells","volume":"10","author":"Khodadadi","year":"2019","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.msard.2025.106887_bib0016","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200211","article-title":"Multiple sclerosis, Rituximab, hypogammaglobulinemia, and risk of infections","volume":"11","author":"Langer-Gould","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.msard.2025.106887_bib0017","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000825","article-title":"Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?","volume":"7","author":"Maarouf","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106887_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2023.578066","article-title":"Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSD","volume":"377","author":"Mears","year":"2023","journal-title":"J. Neuroimmunol."},{"issue":"6","key":"10.1016\/j.msard.2025.106887_bib0019","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1017\/cjn.2024.21","article-title":"Hypogammaglobulinemia and infection risk in an ocrelizumab-treated multiple sclerosis cohort","volume":"51","author":"Nobile","year":"2024","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106887_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106762","article-title":"Suboptimal dose of approved disease modifying therapies in management of patients with multiple sclerosis: a systematic review","volume":"104","author":"Paybast","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106887_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104400","article-title":"Infection risk in a real-world cohort of patients treated with long-term B-cell depletion for autoimmune neurologic disease","volume":"68","author":"Peters","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106887_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105028","article-title":"Ocrelizumab B-cell repopulation-guided extended interval dosing versus standard dosing \u2013 similar clinical efficacy with decreased immunoglobulin M deficiency rates","volume":"79","author":"Rempe","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106887_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103358","article-title":"Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: a systematic review and meta-analysis","volume":"57","author":"Schiavetti","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.msard.2025.106887_bib0024","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.medj.2023.05.001","article-title":"Impact of extended interval dosing of ocrelizumab on immunoglobulin levels in multiple sclerosis","volume":"4","author":"Schuckmann","year":"2023","journal-title":"Med."},{"issue":"7","key":"10.1016\/j.msard.2025.106887_bib0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11940-021-00677-1","article-title":"Early aggressive treatment approaches for multiple sclerosis","volume":"23","author":"Simpson","year":"2021","journal-title":"Curr. Treat. Options. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2025.106887_bib0026","doi-asserted-by":"crossref","first-page":"5479","DOI":"10.1007\/s10072-022-06197-3","article-title":"Comparative safety of high-efficacy disease-modifying therapies in relapsing\u2013remitting multiple sclerosis: a systematic review and network meta-analysis","volume":"43","author":"\u015aladowska","year":"2022","journal-title":"Neurol. Sci."},{"issue":"10","key":"10.1016\/j.msard.2025.106887_bib0027","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1111\/ene.14690","article-title":"COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response","volume":"28","author":"Zabalza","year":"2021","journal-title":"Eur. J. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482500625X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482500625X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T07:47:35Z","timestamp":1781509655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482500625X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":26,"alternative-id":["S221103482500625X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106887","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypogammaglobulinemia and infection risks in multiple sclerosis patients receiving anti-CD20 monoclonal antibodies: Incidence, clinical implications, and longitudinal insights from a three-year Iranian cohort","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106887","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106887"}}